MetaCap

Amphastar Pharmaceuticals Inc. (AMPH)

NASDAQ: AMPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD

28.25+0.14 (+0.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AMPH stock chart

Technical analysis

Key statistics

All statistics
52-week range
16.65 – 31.00
Day range
27.79 – 28.70
Volume / Avg
497.44K / 475.35K
Beta
—

52-week range

$16.65$31.00

AMPH stock today

On Nov 20, AMPH ended the session at $28.25, adding $0.14 (0.50%), versus the S&P 500's 3.70% decline. At this level, AMPH sits near the top of its 52-week range of $16.65 to $31.00: 8.9% below the high, set on Nov 6, 2026 and 69.7% above the low. AMPH is up 5.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.6%.

Amphastar Pharmaceuticals trades at 13.0x its trailing twelve-month earnings per share of $2.18. Its forward P/E of 8.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Amphastar Pharmaceuticals

Company profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Yongfeng Zhang Ph.D.
Headquarters
Rancho Cucamonga, CA
Employees
1,976
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Amphastar Pharmaceuticals generated $719.9 million in revenue, down 1.7% from fiscal 2024, its first annual decline since 2017. Net income was $98.1 million (-38.5% year over year), for a net margin of 13.6% versus a median of 18.3% in the prior 5 years. Gross margin was 49.5% (down from 51.1%) and operating margin 19.5%.

Amphastar Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$719.89M$731.97M$644.39M$498.99M$437.77M
Growth-1.65%+13.59%+29.14%+13.98%+25.13%
Net income$98.09M$159.52M$137.54M$91.39M$62.12M
EPS (diluted)$2.03$3.06$2.60$1.74$1.25

Analyst forecast

Forecast

Consensus (7 analysts)

hold

Avg. price target

$24.50-13.27%

  • Strong buy 0
  • Buy 0
  • Hold 6
  • Sell 0
  • Strong sell 1

Target range

Low $20.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.87 vs $0.80
Surprise
+8.75%

AMPH news

All AMPH news

Amphastar Pharmaceuticals peers

Health Care sector
AMPH peer companies
CompanyPrice% ChgMarket capCompare
GHRSGH Research PLC17.53-5.55%$1.20Bvs AMPH
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs AMPH
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs AMPH
GENBGenerate Biomedicines Inc.9.54-8.00%$1.23Bvs AMPH
OPKOPKO Health Inc.1.57-2.48%$1.17Bvs AMPH
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs AMPH
MNKDMannKind Corporation3.85-2.53%$1.24Bvs AMPH
GPCRStructure Therapeutics Inc. ADR16.13-5.78%$1.15Bvs AMPH

Indexes, lists and sector

Amphastar Pharmaceuticals stock FAQ

What is Amphastar Pharmaceuticals's stock price today?

AMPH last traded at $28.25 as of Nov 20, 4:00 PM EST, up 0.50% on the day. Prices are delayed at least 15 minutes.

What is AMPH's P/E ratio?

AMPH trades at a trailing P/E ratio of 12.96 and a forward P/E of 8.43.

Who is Amphastar Pharmaceuticals's CEO?

Dr. Yongfeng Zhang Ph.D. is the chief executive officer of Amphastar Pharmaceuticals Inc., which has about 1,976 employees.

What is the AMPH 52-week high?

The 52-week high for AMPH is $31.00 and the 52-week low is $16.65. The stock is currently 8.9% below its high.

Compare AMPH